TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34932434

Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy (WEC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Air insufflation colonoscopy (AIC)
Number of subjects: 104
Study: 33761061

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-music group (Control)
Number of subjects: 52
Study: 32952087

Group type: EXPERIMENTAL
Intervention: Pharmacy staff self-reported scores
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Simulated patient (SP) scores
Number of subjects: 270
Study: 36434698

Group type: EXPERIMENTAL
Intervention: Cooking Matters for Parents
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mealtime PREP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined program (Cooking Matters + Mealtime PREP)
Number of subjects: 51
Study: 34020245

Group type: EXPERIMENTAL
Intervention: eHealthResp online course
Number of subjects: 19
Study: 32865944

Group type: EXPERIMENTAL
Intervention: Low-dose topical creatine cream (3.5 ml)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-dose topical creatine cream (7 ml)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Topical creatine cream after 7-day supplementation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo cream after 7-day supplementation
Number of subjects: 123
Study: 36274471

Group type: EXPERIMENTAL
Intervention: Beginning Movement Load Training (BMLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional leg press training
Number of subjects: 20
Study: 33864070

Group type: EXPERIMENTAL
Intervention: Insufficient 25(OH)D (<30 ng/ml)
Number of subjects: 1267

Group type: COMPARATOR
Intervention: iPTH, Ca, FGF23, and 1,25(OH)2D
Number of subjects: 1267
Study: 32553497

Group type: EXPERIMENTAL
Intervention: Voiced High-Frequency Oscillation (VHFO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lax Vox technique
Number of subjects: 30
Study: 32484870

Group type: EXPERIMENTAL
Intervention: Battery of five ADS screening instruments
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Single-item self-report question about having ADS
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Single-item self-report question with added interference belief question
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Battery of screening instruments
Number of subjects: 2637
Study: 35599920

Group type: EXPERIMENTAL
Intervention: Caffeinated MIPS (C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-caffeinated MIPS (NC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34167567

Group type: EXPERIMENTAL
Intervention: Basiliximab induction therapy
Number of subjects: 0
Study: 33290853

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 32479321

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray + newly initiated oral antidepressant (esketamine+AD)
Number of subjects: 0
Study: 33388426

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI) combined with 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI) combined with neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (neoadjuvant chemotherapy without SMI)
Number of subjects: 0
Study: 32389610

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) guidelines for older adults with SCD/MCI
Number of subjects: 22

Group type: COMPARATOR
Intervention: Canadian Physical Activity Guidelines for Older Adults
Number of subjects: 22
Study: 33896815

Group type: EXPERIMENTAL
Intervention: Breathing exercises with core stabilization exercises (BSET)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Stabilization exercises (SET)
Number of subjects: 43
Study: 35581440

Group type: EXPERIMENTAL
Intervention: Aducanumab (32 monthly doses, titrated up to 6 mg/kg, cumulative dose of 186 mg/kg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Aducanumab
Number of subjects: 1
Study: 32414817

Group type: EXPERIMENTAL
Intervention: Learning Together intervention
Number of subjects: 0
Study: 34523872

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SSI) with whole body bed bug extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 20
Study: 32014035

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham transplantation
Number of subjects: 17
Study: 36434148

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for adolescents with CD (MBT-CD)
Number of subjects: 45
Study: 33071262

Group type: EXPERIMENTAL
Intervention: Active learning education program (90-minute sessions for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (90-minute health education class in a didactic manner)
Number of subjects: 60
Study: 32730174

Group type: EXPERIMENTAL
Intervention: High-intensity IMST (75% maximal inspiratory pressure)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control intervention (15% maximum inspiratory pressure)
Number of subjects: 25
Study: 35854800

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lumbar plexus block (LPB)
Number of subjects: 50
Study: 32858033

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 32416981

Group type: EXPERIMENTAL
Intervention: Narcotic group (received acetaminophen, ibuprofen, and narcotic)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nonnarcotic group (received acetaminophen and ibuprofen)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Narcotic group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nonnarcotic group
Number of subjects: 126
Study: 32347143

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 297
Study: 33722312

Group type: EXPERIMENTAL
Intervention: Ca-specific intervention targeted towards parents
Number of subjects: 239

Group type: COMPARATOR
Intervention: Generic dietary advice
Number of subjects: 239
Study: 34975069

Group type: EXPERIMENTAL
Intervention: Scheduled phosphodiesterase 5 inhibitor (PDE5i) 5 mg tadalafil once a day (OaD) combined with vacuum erectile device (VED)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vacuum erectile device (VED) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy of VED and tadalafil OaD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without any intervention
Number of subjects: 100
Study: 34392138

Group type: EXPERIMENTAL
Intervention: Adherence monitoring with audiovisual medication reminders
Number of subjects: 85

Group type: COMPARATOR
Intervention: Adherence monitoring only
Number of subjects: 85
Study: 32201990

Group type: EXPERIMENTAL
Intervention: Virtual reality game of Snakes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Anaglyph intervention
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 18
Study: 36175995

Group type: EXPERIMENTAL
Intervention: Maternal fecal microbiota (FMT) administered orally in breast milk during the first feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment administered orally in breast milk during the first feeding
Number of subjects: 60
Study: 34192430

Group type: EXPERIMENTAL
Intervention: 10 mg ZED1227
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 50 mg ZED1227
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 100 mg ZED1227
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 32466070

Group type: COMPARATOR
Intervention: Standard Release Tacrolimus (SRT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prolonged Release Tacrolimus (PRT)
Number of subjects: 70
Study: 35226523

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 34919838

Group type: EXPERIMENTAL
Intervention: Pragmatic trial interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34016799

Group type: EXPERIMENTAL
Intervention: STrIP score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcutaneous bilirubinometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kramer scale
Number of subjects: 0
Study: 33632110

Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34395716

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g every 6 hours
Number of subjects: 72

Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 hours
Number of subjects: 72
Study: 33123968

Group type: EXPERIMENTAL
Intervention: Trilaciclib 240 mg/m2
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32394350

Group type: EXPERIMENTAL
Intervention: TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Number of subjects: 308

Group type: COMPARATOR
Intervention: EC (epirubicin: 90 mg/m2; cyclophosphamide: 600 mg/m2, day 1) followed by T (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Number of subjects: 308
Study: 33905798

Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 65

Group type: COMPARATOR
Intervention: P-SIMV+PS
Number of subjects: 65
Study: 33731255

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer ($20 per visit)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer ($40 per visit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no cash incentive)
Number of subjects: 100
Study: 36374435

Group type: EXPERIMENTAL
Intervention: HLaC Online intervention (online nutrition, physical activity, and psychosocial support)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HLaC Online intervention (with recommended changes such as simple activities and guidance videos)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HLaC Online intervention
Number of subjects: 27
Study: 33450473

Group type: EXPERIMENTAL
Intervention: CPR video
Number of subjects: 27

Group type: COMPARATOR
Intervention: No video
Number of subjects: 27
Study: 32223479

Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes, 3 times a week at 4 km/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual work and household activities (Control)
Number of subjects: 60
Study: 34692842

Group type: EXPERIMENTAL
Intervention: Lymphocyte active immunotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 124
Study: 35722862

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 118
Study: 33310789

Group type: EXPERIMENTAL
Intervention: eCBTI via a Smartphone application
Number of subjects: 200

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 200
Study: 36410041

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 6662
Study: 34886145

Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: No mask
Number of subjects: 50
Study: 32555559

Group type: EXPERIMENTAL
Intervention: Patients' social and healthcare networks support
Number of subjects: 8
Study: 33562743

Group type: EXPERIMENTAL
Intervention: Isometric abdominal training and gluteus medius-specific training (experimental group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isometric abdominal training (control group)
Number of subjects: 25
Study: 32143552

Group type: EXPERIMENTAL
Intervention: Moses mode
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular mode
Number of subjects: 72
Study: 33964964

Group type: EXPERIMENTAL
Intervention: Researcher time for recruitment and baseline data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment planning and resource allocation
Number of subjects: 0
Study: 32311961

Group type: EXPERIMENTAL
Intervention: Curcuminoid complex 500 mg with diclofenac 50 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Diclofenac 50 mg alone
Number of subjects: 140
Study: 35031148

Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent; QIV-HD)
Number of subjects: 2122
Study: 33475271

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Combination therapy (Ranibizumab with Verteporfin)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 322
Study: 32948224

Group type: EXPERIMENTAL
Intervention: Egg white hydrolyzate (5 g/day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 33866020

Group type: EXPERIMENTAL
Intervention: Active rTMS stimulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 49
Study: 34246687

Group type: EXPERIMENTAL
Intervention: Transmuscular QL block with 20 mL 0.375% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAP block with 20 mL 0.375% ropivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transmuscular QL block
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 80
Study: 35747231

Group type: EXPERIMENTAL
Intervention: Early management (within 1 month)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (∼6 months)
Number of subjects: 200
Study: 35417636

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 526
Study: 33980526

Group type: EXPERIMENTAL
Intervention: Early calorie-protein restriction (6 kcal/kg/day, 0.2-0.4 g/kg/day)
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Standard calorie-protein targets (25 kcal/kg/day, 1.0-1.3 g/kg/day)
Number of subjects: 3044
Study: 33475577

Group type: EXPERIMENTAL
Intervention: Extraoral approach (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraoral approach (Group B)
Number of subjects: 100
Study: 88026749

Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 600000

Group type: COMPARATOR
Intervention: No HBV vaccination (Control)
Number of subjects: 600000
Study: 35927162

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 79
Study: 33929805

Group type: EXPERIMENTAL
Intervention: Keratoconus (KC) prevalence screening
Number of subjects: 585
Study: 36158129

Group type: EXPERIMENTAL
Intervention: Serum pepsinogen I (PGI) and pepsinogen II (PGII) levels in Hp-infected gastric cancer patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum TNF-α, IL-6, and IL-18 levels in Hp-infected gastric cancer patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis of independent risk factors for gastric cancer
Number of subjects: 100
Study: 34041932

Group type: EXPERIMENTAL
Intervention: Experimental vaccine (details not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator vaccine with established efficacy of 50%-70%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator vaccine with established efficacy of 90%-95%
Number of subjects: 0
Study: 33334479

Group type: EXPERIMENTAL
Intervention: VR-based safety training
Number of subjects: 119

Group type: COMPARATOR
Intervention: HFST training
Number of subjects: 119
Study: 35100468

Group type: EXPERIMENTAL
Intervention: Alb‐NC (cerium oxide nanoparticles conjugated with albumin; 50 µg/ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated grafts)
Number of subjects: 9
Study: 32021148

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Number of subjects: 729

Group type: COMPARATOR
Intervention: Glycopyrrolate (GP) MDI 18 µg
Number of subjects: 729

Group type: COMPARATOR
Intervention: Formoterol fumarate (FF) MDI 9.6 µg
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 729
Study: 35294962

Group type: EXPERIMENTAL
Intervention: Cocoa extract supplement (500 mg flavanols/d, including 80 mg (‐)‐epicatechin)
Number of subjects: 21442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21442

Group type: EXPERIMENTAL
Intervention: Cocoa extract supplement
Number of subjects: 21442
Study: 33340120

Group type: EXPERIMENTAL
Intervention: mexiletine 300 or 600 mg daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 36204512

Group type: EXPERIMENTAL
Intervention: Targeted care plus exercise intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 96
Study: 32468131

Group type: EXPERIMENTAL
Intervention: Home-based exercise using a DVD
Number of subjects: 237
Study: 32762718

Group type: EXPERIMENTAL
Intervention: Fire needle plus cupping (FC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Famciclovir plus gabapentin (FG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fire needle plus cupping plus famciclovir (FCF)
Number of subjects: 105
Study: 36858705

Group type: EXPERIMENTAL
Intervention: MPCs (mesenchymal precursor cells)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 565
Study: 32779246

Group type: EXPERIMENTAL
Intervention: iMBGrp3
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: iMBSHH
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subtype II
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subtype VII and IV
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: iMBSHH-II
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: iMBSHH-I and iMBSHH-II
Number of subjects: 387
Study: 33409020

Group type: EXPERIMENTAL
Intervention: Increasing fluid therapy before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 33294988

Group type: EXPERIMENTAL
Intervention: Shade coffee farms with larger, older trees
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Climate changes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bryophyte cover
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tree size and diversity
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Agroforests
Number of subjects: 33
Study: 32105616

Group type: EXPERIMENTAL
Intervention: Costochondral graft (CCG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transport disk distraction osteogenesis (TDDO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both CCG and TDDO
Number of subjects: 24
Study: 34505919

Group type: EXPERIMENTAL
Intervention: Enriched meal with 20g powder (8.1g β-glucans) of oven-dried Pleurotus ostreatus
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control meal without enrichment
Number of subjects: 22
Study: 33247534

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy (15.5 Fr)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rigid cystoscopy (15.5 Fr)
Number of subjects: 41
Study: 34183577

Group type: EXPERIMENTAL
Intervention: 4-week TEA treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute TEA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute and chronic TEA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic TEA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TEA treatment
Number of subjects: 30
Study: 32013700

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 200 mg/kg divided over 24 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35752012

Group type: EXPERIMENTAL
Intervention: Experimental group performing safety behavior toward innocuous stimulus
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no safety behavior)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Experimental group performing safety behavior toward innocuous stimulus (Study 2)
Number of subjects: 68
Study: 33596538

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Combined Physical Rehabilitation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All groups (including VRT, Combined Physical Rehabilitation, Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VRT
Number of subjects: 54
Study: 32451267

Group type: EXPERIMENTAL
Intervention: Acid etchant+Transbond XT™
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vertise Flow™
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acid etchant+Vertise Flow™
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sandblasting (surface treatment)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (surface treatment)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Er:YAG laser (surface treatment)
Number of subjects: 48
Study: 35178708

Group type: EXPERIMENTAL
Intervention: Systemic Family Therapy added to Treatment As Usual
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment As Usual alone
Number of subjects: 60
Study: 34633405

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally once daily; n=164)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose apixaban (2.5 mg orally twice daily; n=165)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban (5 mg orally twice daily; n=164)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Placebo (n=164)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose apixaban
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban
Number of subjects: 7000
Study: 32436135

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy with sulfurous-arsenical-ferruginous mineral water
Number of subjects: 212
Study: 32613672

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (NAs)
Number of subjects: 76
Study: 34726324

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Metformin 1500 to 2000 mg daily
Number of subjects: 68